Group 1 - RBC Capital Markets initiated coverage of Kymera Therapeutics (NASDAQ:KYMR) with an Outperform rating [5] - The focus is on the potential of its lead drug KT-621, which targets inflammatory conditions such as atopic dermatitis (eczema) [5]